IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
Rhea-AI Summary
IDEAYA Biosciences (Nasdaq: IDYA) has nominated IDE892 as a development candidate, representing their 7th development candidate overall. IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor designed for treating MTAP-deletion solid tumors.
The compound demonstrates favorable drug-like properties and has shown exceptional selective antiproliferative activity in MTAP-deleted tumor cell models. When combined with MAT2A inhibitor IDE397, it achieved durable complete responses in preclinical models.
The company is currently conducting IND-enabling studies and targets an IND filing with the FDA in mid-2025, subject to successful completion of ongoing preclinical studies.
Positive
- Development of IDE892 advances company's strategic objective for combination therapy
- IDE892 shows strong preclinical efficacy with complete responses in combination with IDE397
- Compound demonstrates favorable potency, selectivity, and drug-like properties
Negative
- IND filing not expected until mid-2025, indicating lengthy development timeline
- IND filing contingent on successful completion of ongoing studies
News Market Reaction 1 Alert
On the day this news was published, IDYA declined 0.22%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable ADME properties; demonstrating robust MTAP deletion-specific pathway suppression and highly durable antitumor activity in combination with IDE397
- IND-enabling studies ongoing and targeting IND-filing for IDE892 in mid-2025
"We continue to expand our precision medicine oncology pipeline and are excited to nominate our 7th development candidate in IDE892, a potential best-in-class MTA-cooperative PMRT5 inhibitor. IDE892 advances our strategic objective to enable a wholly owned combination between the PRMT5 and MAT2A mechanisms, to deliver potentially greater efficacy in MTAP-deletion solids tumors through this rational combination approach," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences. "Following extensive structure-based design and lead optimization, we have achieved our target product profile for the PRMT5 program with IDE892, including favorable potency, selectivity, and synergistic combination potential with MAT2A inhibitor IDE397," said Michael White, Ph.D., Chief Scientific Officer, IDEAYA Biosciences.
IDE892 was discovered through IDEAYA's iterative physics-based ligand design and optimization platform, and is a highly potent and selective MTA-cooperative PRMT5 inhibitor with best-in-class potential and favorable drug-like properties. IDE892 has demonstrated exceptionally selective antiproliferative activity in MTAP-deleted tumor cell models and durable complete responses in combination with MAT2A inhibitor IDE397 in challenging MTAP-deletion preclinical models. IND-enabling studies for IDE892 are ongoing to support an Investigational New Drug (IND) filing to the
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing of an IND filing with the US FDA and (ii) the potential efficacy, safety and therapeutic benefits of IDEAYA's PRMT5 as a monotherapy and in combination with MAT2A mechanisms, including the MAT2A inhibitor IDE397. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-development-candidate-nomination-of-ide892-a-potential-best-in-class-mta-cooperative-prmt5-inhibitor-302325328.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is IDE892 and when did IDEAYA Biosciences announce its development?
When is IDEAYA Biosciences (IDYA) planning to file IND for IDE892?
What are the key preclinical results for IDEAYA's (IDYA) IDE892?
